Short CommunicationsPharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance)Patel, Jai N.a; Jiang, Chenb; Owzar, Kourosc; Mulkey, Florab; Luzum, Jasmine A.d; Mamon, Harvey J.e; Haller, Daniel G.f; Dragovich, Tomislavg; Alberts, Steven R.h; Bjarnason, Georgi; Willet, Christopher G.j; Niedzwiecki, Donnac; Enzinger, Petere; Ratain, Mark J.k; Fuchs, Charlesl; McLeod, Howard L.mAuthor Information aDepartment of Cancer Pharmacology and Pharmacogenomics, Levine Cancer Institute, Atrium Health, Charlotte bAlliance Statistics and Data Center cDepartment of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina dDepartment of Clinical Pharmacy, University of Michigan, Ann Arbor, Michigan eDepartment of Radiation Oncology, Dana-Farber/Partners CancerCare, Boston, Massachusetts fDepartment of Gastrointestinal Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania gDepartment of Hematology/Oncology, Banner MD Anderson Cancer Center, Gilbert, Arizona hDepartment of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA iDepartment of Medical Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada jDepartment of Radiation Oncology, Duke University School of Medicine, Durham, North Carolina kCenter for Personalized Therapeutics, University of Chicago, Chicago, Illinois lDepartment of Medical Oncology, Smilow Cancer Hospital, Yale University, New Haven, Connecticut mDepartment of Precision Medicine, USF Taneja College of Pharmacy and the Geriatric Oncology Consortium, Tampa, Florida, USA Received 27 October 2020 Accepted 11 December 2020 Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website, www.pharmacogeneticsandgenomics.com. Correspondence to Jai N. Patel, PharmD, BCOP, CPP, Levine Cancer Institute, Atrium Health, 1021 Morehead Medical Drive, Charlotte, NC 28204, USA, Tel: +980442 4113; fax: 980 442 4111; e-mail: [email protected] Pharmacogenetics and Genomics: December 2021 - Volume 31 - Issue 9 - p 215-220 doi: 10.1097/FPC.0000000000000442 Buy SDC Metrics Abstract There is a lack of pharmacogenetic predictors of outcome in gastric cancer patients. The aim of this study was to assess previously identified candidate genes associated with 5-fluorouracil (5-FU), cisplatin, or epirubicin toxicity or response in a cohort of resected gastric cancer patients treated on CALGB (Alliance) 80101. Gastric or gastroesophageal cancer patients randomized to adjuvant 5-FU/leucovorin or epirubicin/cisplatin/5-FU before and after 5-FU chemoradiation were genotyped for single nucleotide polymorphisms (SNPs) in GSTP1 (rs1695), ERCC1 (rs11615 and rs3212986), XRCC1 (rs25487), UGT2B7 (rs7439366) and the 28 base-pair tandem repeats in TYMS (rs34743033). Logistic regression and log rank tests were used to assess the association between each SNP and incidence of grade 3/4 neutropenia and leukopenia, overall (OS) and progression-free survival (PFS), respectively. Toxicity endpoint analyses were adjusted for the treatment arm, while OS and PFS were also adjusted for performance status, sex, age, lymph node involvement, and primary tumor site and size. Of 281 subjects with successful genotyping results and available clinical (toxicity and efficacy) data, 166 self-reported non-Hispanic White patients were included in the final analysis. There was a lack of evidence of an association among any SNPs tested with grade 3/4 neutropenia and leukopenia or OS and PFS. Age, lymph node involvement, and primary tumor size were significantly associated with OS and PFS. This study failed to confirm results of previous gastric cancer pharmacogenetic studies. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.